Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16874568 | 1.00 | LMNA (0.46) | LMNAKDM4EALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL16874630 | 0.76 | SIGMAR1 (0.49) | KDM4EALDH1A1L3MBTL1SIGMAR1KMT2A | |
| SCHEMBL7247690 | 0.75 | L3MBTL1 (0.44) | ALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL16874556 | 0.74 | SIGMAR1 (0.54) | LMNAKDM4EALDH1A1SIGMAR1KMT2A | |
| SCHEMBL16874555 | 0.74 | SIGMAR1 (0.54) | LMNAKDM4EALDH1A1SIGMAR1KMT2A | |
| SCHEMBL16892067 | 0.74 | HCRTR1 (0.44) | KDM4EALDH1A1SIGMAR1KMT2AMEN1 | |
| SCHEMBL23310902 | 0.71 | KMT2A (0.43) | LMNAKDM4EALDH1A1SIGMAR1KMT2A | |
| SCHEMBL13108667 | 0.70 | HCRTR1 (0.65) | ALDH1A1L3MBTL1SIGMAR1KMT2AMEN1 | |
| SCHEMBL13397599 | 0.70 | HCRTR1 (0.65) | ALDH1A1L3MBTL1SIGMAR1KMT2AMEN1 | |
| SCHEMBL13099493 | 0.70 | HCRTR1 (0.65) | ALDH1A1L3MBTL1SIGMAR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191452-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | LMNA 3807/4885KDM4E 4042/4885ALDH1A1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.